Skip to main content
. 2014 Jan 1;3:e27401. doi: 10.4161/onci.27401

graphic file with name onci-3-e27401-g1.jpg

Figure 1. Enhancing immune responses against lung cancer by targeting myeloid-derived suppressor cells. The combination of gemcitabine and a superoxide dismutase mimetic inhibits the activity of myeloid-derived suppressor cells (MDSCs), modulates redox signaling and enhances the quantity, quality and persistence of memory CD8+ T cells.